CA2064861A1 - Galenique injectable a effet retarde - Google Patents

Galenique injectable a effet retarde

Info

Publication number
CA2064861A1
CA2064861A1 CA2064861A CA2064861A CA2064861A1 CA 2064861 A1 CA2064861 A1 CA 2064861A1 CA 2064861 A CA2064861 A CA 2064861A CA 2064861 A CA2064861 A CA 2064861A CA 2064861 A1 CA2064861 A1 CA 2064861A1
Authority
CA
Canada
Prior art keywords
galenical
nervous system
slow
recipient
injectable slow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2064861A
Other languages
English (en)
Other versions
CA2064861C (fr
Inventor
Juan Angeles Uribe
Josue Garza Flores
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aplicaciones Farmaceuticas SA de CV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2064861A1 publication Critical patent/CA2064861A1/fr
Application granted granted Critical
Publication of CA2064861C publication Critical patent/CA2064861C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Abstract

Formulation à libération retardée destinée à l'administration par injection parentérale, constituée de microsphères calibrées solides (5-300 µm) comprenant une substance pharmaceutiquement active (par exemple: morphine) contenue dans des structures sphériques formées par une ou plusieurs substances-support pharmacologiquement inactives (par exemple: cholestérol) présentes naturellement dans l'organisme receveur, pharmacodynamiquement inactives aux doses d'administration de ladite forme galénique, ayant un point de fusion supérieur à 60 °C et stables à l'état solide dans le milieu physiologique receveur. La forme galénique permet de ralentir et de prolonger l'effet de substances actives trop rapidement solubles en milieu physiologiques (agissant sur le système nerveux central ou neuro-végétatif, comme vasodilatateurs, antihistaminiques, hormones, anticonceptifs...).
CA002064861A 1990-06-14 1991-06-12 Galenique injectable a effet retarde Expired - Fee Related CA2064861C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9007417 1990-06-14
FR9007417A FR2663224B1 (fr) 1990-06-14 1990-06-14 Forme galenique parenterale.
PCT/EP1991/001097 WO1991019485A1 (fr) 1990-06-14 1991-06-12 Forme galenique injectable retardee

Publications (2)

Publication Number Publication Date
CA2064861A1 true CA2064861A1 (fr) 1991-12-15
CA2064861C CA2064861C (fr) 2000-08-01

Family

ID=9397599

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002064861A Expired - Fee Related CA2064861C (fr) 1990-06-14 1991-06-12 Galenique injectable a effet retarde

Country Status (33)

Country Link
US (1) US5643604A (fr)
EP (1) EP0487674B1 (fr)
JP (1) JP2690398B2 (fr)
KR (1) KR0157438B1 (fr)
CN (1) CN1058608C (fr)
AT (1) ATE117546T1 (fr)
AU (1) AU643540B2 (fr)
BG (1) BG61178B1 (fr)
BR (1) BR9105782A (fr)
CA (1) CA2064861C (fr)
CZ (1) CZ286199B6 (fr)
DE (1) DE69107026T2 (fr)
DK (1) DK0487674T3 (fr)
ES (1) ES2068592T3 (fr)
FI (1) FI107697B (fr)
FR (1) FR2663224B1 (fr)
GR (1) GR3015809T3 (fr)
HU (1) HU219461B (fr)
IE (1) IE69172B1 (fr)
IL (1) IL98458A (fr)
NO (2) NO302927B1 (fr)
NZ (1) NZ238543A (fr)
PH (1) PH30243A (fr)
PL (1) PL167177B1 (fr)
PT (1) PT97976B (fr)
RO (1) RO110198B1 (fr)
RU (1) RU2095055C1 (fr)
SK (1) SK279867B6 (fr)
TN (1) TNSN91047A1 (fr)
TW (1) TW205511B (fr)
UY (1) UY23239A1 (fr)
WO (1) WO1991019485A1 (fr)
ZA (1) ZA914549B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9819272D0 (en) * 1998-09-03 1998-10-28 Andaris Ltd Microparticles
CN1187039C (zh) 1999-03-26 2005-02-02 波曾公司 高效双氢麦角胺组合物
DE50202200D1 (de) * 2001-09-27 2005-03-17 Cognis Deutschland Gmbh Kugelförmige Sterinzubereitungen, deren Herstellung und Verwendung
EP1448228A4 (fr) * 2001-10-24 2007-01-24 Marco Pappagallo Traitement de la douleur postoperatoire
MXPA04006017A (es) * 2001-12-20 2005-06-08 Femmepharma Inc Suministro de farmacos por via vaginal.
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
KR20050086948A (ko) * 2002-12-27 2005-08-30 디오벡스, 인코포레이티드 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
EP1578421A4 (fr) * 2003-01-02 2009-04-22 Femmepharma Holding Co Inc Preparations pharmaceutiques permettant le traitement de maladies et d'affections du sein
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US7589082B2 (en) 2003-06-13 2009-09-15 Skendi Finance Ltd Pharmaceutical formulation for contraception and hormone-replacement therapy
US7413690B1 (en) 2003-10-29 2008-08-19 The University Of Mississippi Process and apparatus for producing spherical pellets using molten solid matrices
PL1838716T3 (pl) 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
WO2007072491A2 (fr) * 2005-12-21 2007-06-28 Baskaran Chandrasekar Formulation pharmaceutique a liberation prolongee et traitement des cardiopathies ischemiques par l’administration de celle-ci
KR20090094336A (ko) 2006-11-27 2009-09-04 하. 룬트벡 아크티에 셀스카브 헤테로아릴 아미드 유도체
CA2674078C (fr) * 2006-12-26 2012-03-20 Femmepharma Holding Company, Inc. Administration topique de danazol
CN102056611A (zh) 2008-04-14 2011-05-11 Posi维森纳里解决方案有限责任公司 用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
UY33103A (es) 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
PL2523666T3 (pl) * 2010-01-14 2016-06-30 Asarina Pharma Ab Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-5-alfa-pregnan-20-on o ulepszonych właściwościach przechowywania i rozpuszczalności
RU2576236C1 (ru) * 2014-08-22 2016-02-27 Александр Александрович Кролевец Способ получения нанокапсул антибиотиков в агар-агаре
RU2577689C1 (ru) * 2014-08-26 2016-03-20 Александр Александрович Кролевец Способ получения нанокапсул антибиотиков в агар-агаре
RU2578408C1 (ru) * 2014-09-10 2016-03-27 Александр Александрович Кролевец Способ получения нанокапсул алкалоидов
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
DK123067B (da) * 1970-09-25 1972-05-15 Niro Atomizer As Fremgangsmåde til behandling af et pulverformigt, fedtholdigt mælkeprodukt.
JPS5017525A (fr) * 1973-06-14 1975-02-24
US3982537A (en) * 1974-12-30 1976-09-28 Louis Bucalo Dynamic implants and method for implanting the same
CA1077842A (fr) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Excipient albumineux pour medicament
IT1202370B (it) * 1976-07-12 1989-02-09 Hoffmann La Roche Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti
US4357259A (en) * 1977-08-01 1982-11-02 Northwestern University Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres
US4244949A (en) * 1978-04-06 1981-01-13 The Population Council, Inc. Manufacture of long term contraceptive implant
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
FR2524312B1 (fr) * 1982-04-01 1985-10-04 Tech Cuir Centre Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
JPS61174940A (ja) * 1985-01-29 1986-08-06 Oogawara Kakoki Kk ワックス類コーテイング単核状マイクロカプセルおよびその製造方法
US4675173A (en) * 1985-05-08 1987-06-23 Molecular Biosystems, Inc. Method of magnetic resonance imaging of the liver and spleen
IL79407A (en) * 1985-08-01 1991-03-10 Theragenics Corp System and method for delivering insoluble material into a living body
ATE74009T1 (de) * 1986-08-11 1992-04-15 American Cyanamid Co Zusammensetzungen zur parenteralen verabreichung und deren verwendung.
US4837381A (en) * 1986-08-11 1989-06-06 American Cyanamid Company Compositions for parenteral administration and their use
CA1319886C (fr) * 1987-02-03 1993-07-06 Alberto Ferro Solutions de micelles mixtes
US4748024A (en) * 1987-04-06 1988-05-31 Endocon, Inc. Flash flow fused medicinal implants
US4892734A (en) * 1987-04-06 1990-01-09 Endocon, Inc. Dispensing paste for forming medicinal pellets
ATE109941T1 (de) * 1987-04-06 1994-09-15 Endocon Inc Durch schnellschmelzen hergestellte medizinische implantate.
EP0366058A3 (fr) * 1988-10-27 1991-03-20 Abbott Laboratories Dispositif de délivrance à libération contrôlée, procédé de préparation du dispositif et méthode d'utilisation du dispositif
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5085864A (en) * 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.

Also Published As

Publication number Publication date
PT97976B (pt) 1998-11-30
PL290678A1 (en) 1992-06-26
SK279867B6 (sk) 1999-04-13
TNSN91047A1 (fr) 1992-10-25
BG61178B1 (bg) 1997-02-28
PH30243A (en) 1997-02-05
BR9105782A (pt) 1992-08-18
JP2690398B2 (ja) 1997-12-10
JPH05501268A (ja) 1993-03-11
NO920576L (no) 1992-04-08
HUT61458A (en) 1993-01-28
AU8066791A (en) 1992-01-07
KR920702212A (ko) 1992-09-03
PT97976A (pt) 1992-04-30
CZ286199B6 (cs) 2000-02-16
ES2068592T3 (es) 1995-04-16
TW205511B (fr) 1993-05-11
IE69172B1 (en) 1996-08-07
IL98458A0 (en) 1992-07-15
ATE117546T1 (de) 1995-02-15
GR3015809T3 (en) 1995-07-31
US5643604A (en) 1997-07-01
WO1991019485A1 (fr) 1991-12-26
DK0487674T3 (da) 1995-06-26
FI920661A0 (fi) 1992-02-14
ZA914549B (en) 1992-03-25
FR2663224A1 (fr) 1991-12-20
FI107697B (fi) 2001-09-28
AU643540B2 (en) 1993-11-18
RO110198B1 (ro) 1995-11-30
CA2064861C (fr) 2000-08-01
KR0157438B1 (ko) 1998-11-16
CS181591A3 (en) 1992-06-17
PL167177B1 (pl) 1995-08-31
NO302927B1 (no) 1998-05-11
FR2663224B1 (fr) 1995-01-20
HU219461B (hu) 2001-04-28
IE912018A1 (en) 1991-12-18
NZ238543A (en) 1993-08-26
UY23239A1 (es) 1991-07-12
HU9200775D0 (en) 1992-05-28
NO920576D0 (no) 1992-02-13
CN1058608C (zh) 2000-11-22
IL98458A (en) 1995-12-31
EP0487674A1 (fr) 1992-06-03
EP0487674B1 (fr) 1995-01-25
CN1057960A (zh) 1992-01-22
DE69107026D1 (de) 1995-03-09
RU2095055C1 (ru) 1997-11-10
DE69107026T2 (de) 1995-08-31

Similar Documents

Publication Publication Date Title
CA2064861A1 (fr) Galenique injectable a effet retarde
Breimer et al. Pharmacokinetics of benzodiazepines. Short-acting versus long-acting
CA2232450A1 (fr) Composition pharmaceutique administrable par voie orale contenant des agents actifs antimicrobiens et du pantoprazole a liberation differee
EP0102265A3 (en) Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
ES2028492A6 (es) Procedimiento de obtencion de hidrosoles de agentes farmacologicamente activos.
CA2258095A1 (fr) Compositions contenant de la tetrahydrolipstatine
CA2067228A1 (fr) Systeme d'administration de medicaments, methode de preparation et utilisation
RU92016471A (ru) Твердая непористая микросфера, способ ее получения и применение в фармакологическом препарате
UA27043C2 (uk) Мікросферичhі частиhки для пареhтеральhої іh'єкції фармацевтичhо активhої речовиhи при її коhтрольоваhому виділеhhі в оргаhізмі після іh'єкції, спосіб їх одержаhhя та суспеhзія hа осhові даhих мікросфер
DE3750943T2 (de) Teilchenzubereitung mit verzögerter Wirkstoffabgabe und deren Zubereitungsmethode.
ZA98273B (en) Drug delivery composition produced from a mixture of gelatin and chitosan.
CA2136434A1 (fr) Systemes pour la liberation d'un medicament a base d'erythropoietine
HUT55220A (en) Process for producing pharmaceutical composition suitable for systemic administration through the skin and comprising deprenyl as active ingredient
CA2102630A1 (fr) Compositions pharmaceutiques de medicaments compactes
DK0460020T3 (da) Medikamentleveringssammensætninger
ES8607009A1 (es) Un metodo para preparar una forma de dosificacion unitaria solida, terapeuticamente activa
EP0513702A3 (fr) Dérivés de la mélatonine utiles dans le traitement des troubles du sommeil et en pré-anesthésie
KR880010758A (ko) 서방성 제제
CA2274485A1 (fr) Compositions medicinales
IT1243745B (it) Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione.
MA21264A1 (fr) Composition permettant d'administrer un medicament sous forme de gellules, d'une poudre ou d'un liquide.
FR2688405B1 (fr) Procede d'une preparation d'une solution medicinale stable pour voie orale a liberation controlee, a base d'un beta-bloquant, et composition pharmaceutique a base d'un beta-bloquant.
HK1040920A1 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent.
CA2283830A1 (fr) Composition concue pour former des particules solides
FR2615512B1 (fr) Composes de benzamides substitues pharmacologiquement actifs, compositions pharmaceutiques contenant ces composes, et leur procede de preparation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed